Simeon Simeonov

Launched in 2015, Endeavor Bulgaria is the third European affiliate to Endeavor Global. With the support of some of Bulgaria’s top business leaders, Endeavor Bulgaria is focused on supporting the entrepreneurs with the most potential to create jobs and transform the regional economy. Endeavor Bulgaria provides entrepreneurs with access to mentors, market, talent and capital.

TBD Angels is a group of angel investors who are current operators at leading startups and executives at major companies.I We are committed to extending our early-stage financial investments beyond that of a commodity: As recovering / current entrepreneurs and leaders passionate about helping early stage ventures, we strive to share our deep and varied experiences in operating startup ventures. We look forward to lending a helping hand to entrepreneurs on a path to change the world!

Launched in 2015, Endeavor Bulgaria is the third European affiliate to Endeavor Global. With the support of some of Bulgaria’s top business leaders, Endeavor Bulgaria is focused on supporting the entrepreneurs with the most potential to create jobs and transform the regional economy. Endeavor Bulgaria provides entrepreneurs with access to mentors, market, talent and capital.

TBD Angels is a group of angel investors who are current operators at leading startups and executives at major companies.I We are committed to extending our early-stage financial investments beyond that of a commodity: As recovering / current entrepreneurs and leaders passionate about helping early stage ventures, we strive to share our deep and varied experiences in operating startup ventures. We look forward to lending a helping hand to entrepreneurs on a path to change the world!

One Way Ventures is a Boston and SF-based seed-stage fund backing exceptional immigrant tech founders in the United States.

IPM.ai, part of Real Chemistry (www.ipm.ai), transforms real world data into real world insights that uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the commercialization of precision therapies for specialty and rare diseases that lead to optimal patient outcomes quicker, with less risk. IPM.ai’s Insights as a Service (IaaS) platform optimizes drug development, clinical study, product launch and commercial operations by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals. We’re making the promise of precision medicine an analytical reality. And we’re just getting started.

Swoop empowers the world’s leading pharmaceutical brands to better-educate patients about disease states and the therapies that could remedy their conditions, as well as enable them to become active participants in their treatment journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement uncovers unique target audiences for precisely activating patient populations and their healthcare ecosystems through cross-channel marketing strategies. By utilizing artificial intelligence, machine learning and evolutionary computation in conjunction with a real world data universe of over 300 million de-identified patients and 65 billion anonymized social determinants of health signals, Swoops segments are superior in audience quality, lead to optimal conversion and drive increase Rx lift.